Pharmaceutical Executives Condemn US Judicial Ruling Outlawing Abortion Pill

Dozens of pharmaceutical executives, including top leaders from Pfizer, Novartis, Biogen, and Merck, have signed a letter criticizing a recent US judicial ruling that could block access to the widely used abortion pill mifepristone. The ruling, issued by Texas federal judge Matthew Kacsmaryk, has been condemned as an attack on the FDA's authority and a threat to the development of new medications in the US. The letter notes that the decision ignores decades of scientific evidence and legal precedent, and could have a chilling effect on investment in new treatments.

Key Takeaways:

400 pharmaceutical executives, including CEO's of Pfizer, Novartis, Biogen, and Merck, signed a letter criticizing the judicial ruling.
The ruling could block access to mifepristone, a medication used by 5.6 million women since 2000.
The letter argues that the ruling ignores decades of scientific evidence and legal precedent.
Judge Kacsmaryk's ruling threatens the FDA's authority over drug approvals and creates uncertainty for the biopharma industry.
The letter warns that adding regulatory uncertainty to the development of new medicines will reduce incentives for investment and endanger innovation.
The US Justice Department has asked a federal appeals court to freeze the ruling.

Statistics:

5.6 million women have used mifepristone since 2000.
The FDA approved mifepristone 23 years ago.
400 pharmaceutical executives signed the letter criticizing the judicial ruling.

Sources:

AFP (Associated Press)